SUPPORT HOTLINE 888-901-2226
Donate Now

Addressing A Projected Limited Supply Of BCG In 2019

BCAN and our Scientific Advisory Board have been advised by Merck & Co., Inc. that they anticipate a limited supply of Bacillus Calmette-Guerin (BCG) in the in the next year.

Due to increasing global demand for BCG treatment and as the only source of TICE BCG in many countries, Merck anticipates supply constraints beginning in the first quarter of 2019. Merck increased production of TICE BCG by more than 100 percent to enable it to be produced at the full extent of their manufacturing capacity. However, even with the increased production, an increasing global demand is leading to supply constraints. To minimize disruption to patient care, Merck will be proportionally allocating the medicine across countries, including the United States. This Merck allocation approach will enable TICE BCG availability in a manner that considers the needs of patients based on historical demand in each country.

BCAN’s Scientific Advisory Board is aware of this issue. If you have concerns about your BCG treatments, please speak with your physician. BCAN is continuing to monitor this and will update you as more information becomes available.

Learn more about how BCG is used to treat bladder cancer here.